We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 12.88 | 1.19% | 1,094.99 | 1,056.35 | 1,100.00 | 1,100.08 | 1,079.0855 | 1,087.89 | 282,365 | 01:00:00 |
From Jul 2019 to Jul 2024
By Michael Dabaie
Sanofi (SNY) and Regeneron Pharmaceuticals Inc. (REGN) said the U.S. Food and Drug Administration approved Dupixent, or dupilumab, for use with other medicines to treat chronic rhinosinusitis with nasal polyposis in adults whose disease isn't controlled.
Sanofi and Regeneron are jointly developing dupilumab under a global collaboration agreement. CRSwNP is a chronic disease of the upper airway that obstructs the sinuses and nasal passages.
Dupilumab is the first biologic medicine for adults with inadequately controlled chronic rhinosinusitis with nasal polyposis, the companies said. Dupixent significantly reduces nasal polyp size and improves congestion and loss of smell, while reducing the need for surgery and systemic corticosteroids, the companies said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
June 26, 2019 14:15 ET (18:15 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
